YOLFTbeta
68

InnoCare Pharma Ltd. A

688428 · SHG · Healthcare / Biotechnology

24.99CNY-1.00 (-3.85%)

Price History

Full chart

Market Stats

Previous Close25.99
Open26.15
Day Range24.86 – 26.25
52-Week Range19.36 – 35.00
Volume6.20M
Market Cap51.44B
P/E (TTM)53.91
Forward P/E212.77
EPS0.54
Dividend Yield0.00%
Beta0.39
50-Day Avg29.10
200-Day Avg25.81

About

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. The company has research collaboration and license agreement with Eli Lilly and Company to develop new medicines. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jisong Cui Ph.D.
  • Employees1.39K
  • HeadquartersBuilding 8, Beijing, China, 102206, China
  • Websitehttps://www.innocarepharma.com

Leadership

  • Dr. Jisong Cui Ph.D.Co-Founder, Chairwoman & CEO · b. 1963
  • Dr. Renbin Zhao Ph.D.Senior VP of Clinical Development & Medical Research and Executive Director · b. 1969
  • Mr. Xin FuChief Financial Officer · b. 1978
  • Mr. Nan GaoChief Operating Officer · b. 1974
  • Yue TanAccounting Supervisor
  • Dr. Xiangyang Chen Ph.D.Chief Technology Officer · b. 1967
  • Ms. Bei YuanJoint Company Secretary & Senior Director of Investor elations
  • Ms. Junsu WangGeneral Counsel · b. 1977
  • Mr. Davy Ouyang Ph.D.VP & Head of Biology
  • Mr. Jeff ChenChief Commercial Officer

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.36M1.04B625.40M738.54M1.01B2.37B
Growth (%)-+76368.70%-40.04%+18.09%+36.68%+135.27%
Cost of Revenue065.67M143.40M128.44M138.44M191.11M
Gross Profit1.36M977.37M482.01M610.10M871.01M2.18B
Gross Margin100.00%93.70%77.07%82.61%86.29%91.95%
Operating Expense495.91M1.14B1.21B1.26B1.40B1.69B
Operating Income-494.55M-166.24M-731.14M-652.51M-525.78M496.00M
Operating Margin-36257.11%-15.94%-116.91%-88.35%-52.09%20.88%
EBITDA---808.28M-516.52M-312.55M828.23M
EBITDA Margin---129.24%-69.94%-30.96%34.87%
Net Income-391.39M-64.55M-886.59M-631.26M-440.63M642.47M
Net Income Margin-28694.65%-6.19%-141.76%-85.47%-43.65%27.05%
R&D402.77M721.58M639.14M751.18M814.03M951.62M
R&D as % of Total Revenue29528.67%69.18%102.20%101.71%80.64%40.07%
Interest Expense1.14M2.64M17.05M35.07M33.79M54.13M
Interest Expense % of Total Revenue83.50%0.25%2.73%4.75%3.35%2.28%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-4.54B7.40B10.32B9.92B9.41B10.82B
Total Liabilities-1.38B1.74B2.68B2.74B2.66B3.07B
Total Equity-3.10B5.60B7.60B7.15B6.73B7.73B
Cash-3.97B5.93B8.70B8.22B6.22B7.05B

Cash Flow

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-172.52M167.06M-565.55M-671.34M-365.55M83.90M
Capital Expenditure251.27M171.21M370.33M254.66M78.23M70.14M
Free Cash Flow-423.79M-4.15M-935.88M-926.00M-443.78M13.77M
FCF to OCF245.65%-2.49%165.48%137.93%121.40%16.41%

Earnings

Report DateNov 14, 2022Mar 27, 2023May 9, 2023Mar 28, 2024May 12, 2024Aug 20, 2024Nov 11, 2024Mar 27, 2025May 13, 2025Jun 30, 2025Nov 13, 2025Mar 25, 2026Apr 23, 2026Jun 30, 2026
EPS Estimate--0.05--0.27-0.27-0.11-0.09-0.090.07-0.10-0.020.40-0.01
EPS Actual-0.22-0.01-0.01-0.06-0.06-0.08-0.01-0.100.01--0.020.420.06-
Surprise-80.00%-77.78%77.78%27.27%88.89%-11.11%-85.71%-0.00%5.00%--
TimingAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap51.44B
Enterprise Value22.76B
Trailing P/E53.91
Forward P/E212.77
Price / Sales18.50
Price / Book7.69
EPS0.54
Book Value4.37
Revenue (TTM)2.78B
Gross Profit (TTM)2.55B
EBITDA778.87M
Profit Margin33.05%
Operating Margin12.47%
Return on Equity12.77%
Return on Assets4.28%
Shares Outstanding273.40M
Shares Float1.17B
Beta0.39
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%